Grifols, S.A. (NASDAQ:GRFS) Receives $10.30 Average Price Target from Brokerages

Shares of Grifols, S.A. (NASDAQ:GRFS) have been assigned a consensus recommendation of “Hold” from the five ratings firms that are currently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $10.30.

Several analysts recently commented on GRFS shares. Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a report on Wednesday, October 8th. Zacks Research lowered shares of Grifols from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Grifols in a research note on Tuesday, August 5th. Finally, Wall Street Zen raised Grifols from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th.

Grifols Stock Up 3.7%

Shares of Grifols stock opened at $8.67 on Friday. The company has a current ratio of 2.64, a quick ratio of 0.95 and a debt-to-equity ratio of 1.20. Grifols has a 1 year low of $6.19 and a 1 year high of $11.14. The stock has a 50-day moving average price of $9.30 and a 200 day moving average price of $9.36. The company has a market cap of $5.96 billion, a P/E ratio of 45.63, a P/E/G ratio of 0.32 and a beta of 0.69.

Institutional Investors Weigh In On Grifols

Several large investors have recently made changes to their positions in GRFS. Brandes Investment Partners LP raised its position in Grifols by 8.9% during the second quarter. Brandes Investment Partners LP now owns 28,035,461 shares of the biotechnology company’s stock valued at $253,441,000 after acquiring an additional 2,294,113 shares in the last quarter. Capital World Investors boosted its holdings in Grifols by 5.9% in the third quarter. Capital World Investors now owns 22,926,140 shares of the biotechnology company’s stock worth $228,344,000 after purchasing an additional 1,273,391 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Grifols by 1.9% during the first quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company’s stock worth $29,948,000 after buying an additional 80,507 shares during the last quarter. Bank of America Corp DE raised its holdings in Grifols by 32.3% during the third quarter. Bank of America Corp DE now owns 3,992,804 shares of the biotechnology company’s stock valued at $39,768,000 after buying an additional 975,129 shares in the last quarter. Finally, Bank of Montreal Can lifted its position in shares of Grifols by 3,205.1% in the third quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock worth $30,017,000 after buying an additional 2,922,540 shares during the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.